Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, Cova A, Camerini R, Lewis JJ, Srivastava PK, Parmiani G. Rivoltini L, et al. Among authors: srivastava pk. J Immunol. 2003 Oct 1;171(7):3467-74. doi: 10.4049/jimmunol.171.7.3467. J Immunol. 2003. PMID: 14500642
Heat shock proteins and their use as anticancer vaccines.
Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, Belli F, Mazzaferro V, Coppa J, Patuzzo R, Sertoli MR, Hoos A, Srivastava PK, Santinami M. Parmiani G, et al. Among authors: srivastava pk. Clin Cancer Res. 2004 Dec 15;10(24):8142-6. doi: 10.1158/1078-0432.CCR-04-1194. Clin Cancer Res. 2004. PMID: 15623587 Review. No abstract available.
Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM, Bona RD, Fang M, Hegde U, Moyo V, Tannenbaum SH, Ménoret A, Gaffney J, Glynn L, Runowicz CD, Srivastava PK. Li Z, et al. Among authors: srivastava pk. Clin Cancer Res. 2005 Jun 15;11(12):4460-8. doi: 10.1158/1078-0432.CCR-05-0250. Clin Cancer Res. 2005. PMID: 15958631 Clinical Trial.
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G. Pilla L, et al. Among authors: srivastava pk. Cancer Immunol Immunother. 2006 Aug;55(8):958-68. doi: 10.1007/s00262-005-0084-8. Epub 2005 Oct 8. Cancer Immunol Immunother. 2006. PMID: 16215718 Free PMC article. Clinical Trial.
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK; C-100-21 Study Group. Testori A, et al. Among authors: srivastava pk. J Clin Oncol. 2008 Feb 20;26(6):955-62. doi: 10.1200/JCO.2007.11.9941. J Clin Oncol. 2008. PMID: 18281670 Clinical Trial.
547 results